Clinical trial
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
NCT07923747 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started December 2026. Interventional study, Phase 1, 90 participants (estimated). Lead sponsor Novartis Pharmaceuticals. Primary measure: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs).
How it compares
267 similar trials: same condition (Lupus Erythematosus, Systemic) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
- Official title
- A Two-part, First-In-Human, Phase I, Open-label, Ascending Dose Study to Assess Safety and Tolerability of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- February 21, 2029
- Enrollment
- 90 (estimated)
- Sites
- Not reported
Conditions
MeSH condition names; the registry's own terms follow.
Arthritis, Rheumatoid, Lupus Erythematosus, Systemic
Registry terms: rheumatoid arthritis and systemic lupus erythematosus
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Lead sponsor
- Novartis Pharmaceuticals
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Part A- Cohort A-DKB903 | Experimental | DKB903 |
Show registry wordingParticipants will receive DKB903 at escalating dose levels. | ||
| Part B- Cohort B-DKB903 dose level identified as safe in Part A | Experimental | DKB903 |
Show registry wordingDKB903 dose level identified as safe in Part A, plus up to two additional full doses. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | From Day 1 up to approximately 2 years. |
Show registry wordingNumber of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs. | |
Lead sponsor's other trials
Novartis Pharmaceuticals, most recent start first.
+3,426 more trials See the organization page
Similar trials
Same condition (Lupus Erythematosus, Systemic) and phase, most recent start first.
+262 more trials See the condition page